BeOne Medicines Ltd. (ONC), a prominent player in the biotechnology sector, is making waves with its remarkable potential upside of 32.22%, as highlighted by analyst ratings. Based in Basel, Switzerland,..
Investors with an eye for biotechnology stocks are closely watching BeOne Medicines Ltd. (ONC), a Swiss-based oncology company that’s making waves with its innovative cancer treatments. With a significant market..
BeOne Medicines Ltd. (ONC), a Switzerland-based biotechnology company, is making significant strides in the healthcare sector, particularly in oncology. With a market capitalization of $28.04 billion and a diverse portfolio..
For investors searching for promising opportunities in the biotechnology sector, BeOne Medicines Ltd. (ONC) stands out with a potential upside of 34.36% according to analyst ratings. Based in Basel, Switzerland,..
BeOne Medicines Ltd. (ONC), a Switzerland-based biotechnology company, is making significant waves in the healthcare sector with its innovative approach to oncology. With a market capitalization of $31.32 billion, BeOne..
BeOne Medicines Ltd. (ONC), a prominent player in the biotechnology sector, is catching the attention of investors with a compelling potential upside of 29.81% as per analyst ratings. Based in..
BeOne Medicines Ltd. (ONC), a Swiss biotechnology firm specializing in oncology, is capturing investor attention with a promising 35.69% potential upside. The company, formerly known as BeiGene, Ltd., has been..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced that it has been awarded the Queen’s Award for Enterprise 2022 in the innovation category, endorsing Oncimmune as a..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has today announced the signing of a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science,..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its unaudited interim results for the six months ended 30 November 2021. Financial highlights · Recognised revenue for the period was..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company, focusing on the autoantibody..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has today announced it has signed a further commercial contract under its existing master services agreement with a top five global..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication of a paper entitled: “Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection” 1 arising from the..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that the Company has signed further commercial contracts within its ImmunoINSIGHTS pharma services business. MSA and Commercial Contract Signed with..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today provided an update on commercial activity within its ImmunoINSIGHTS pharma services business. As we highlighted in the full year results..
